skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Farletuzumab (Code C61503)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Farletuzumab

Definition: A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.

Display Name: Farletuzumab

Label: Farletuzumab

NCI Thesaurus Code: C61503 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2700602  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
CAS Registry Number 896723-44-7 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 486728
PDQ Open Trial Search ID 486728 (check for NCI PDQ open clinical trial info)
UMLS CUI C2700602

Other Properties:
     Name Value (qualifiers indented underneath)
code C61503
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-GP-3_Monoclonal_Antibody
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom